Supporting real-world usability and adoption
Supporting real-world usability and adoption
Our AI Breast Tool Assessment Service provides critical evidence required to prepare your technology for regulatory approval. We specialise in rigorously testing AI breast radiology tools and comparing performance against the ground truth, delivering objective data that confirms accuracy, reliability, and real-world readiness. Leveraging comprehensive, real-world up-to-date datasets from multiple NHS centres across the UK, our assessment service exclusively uses these datasets to provide a robust and representative comparison with baseline data.
Our team of NHS clinical computing scientists and AI standards experts work together to rigorously assess your AI tool, ensuring it meets both regulatory and clinical needs.
Unlike site-specific validations, we assess your tool against a centralised, NHS-representative dataset, demonstrating performance across diverse healthcare settings while saving time and resources.
Our process delivers comprehensive results promptly, allowing you to refine your tool and progress towards regulatory approval without unnecessary delays.
Our process delivers comprehensive results promptly, allowing you to refine your tool and progress towards regulatory approval without unnecessary delays.
The service supports pre-certification testing and retrospective evidence gathering to support early-stage AI development.
Our assessment methods align with BSI standard BS 30440:2023, providing independent evidence to support your regulatory submission.
By rigorously assessing your AI tool, we provide the objective evidence to increase confidence among healthcare professionals ensuring real-world usability and adoption.
We currently offer our assessment service for AI tools focused on breast images. Your tools will be thoroughly tested against ground truth data from OPTIMAM Mammography Image Database, providing independent validation evidence that can be included in regulatory submissions and support progress toward clinical adoption of AI radiology tools.
At present, we are actively expanding our assessment service to include other disease sites, supporting a broader range of AI radiology tools
Site Selector
Global
Americas
Asia
Europe
Middle East and Africa